Topics of Interest

Medicare B will cover an immunoglobulin therapy for patients with CIDP, starting July 18, 2021

A message from our industry partners at CSL Behring: We are pleased to share that effective July 18, Hizentra®, Immune Globulin Subcutaneous (Human), 20% Liquid, will be covered under Medicare Part B for maintenance therapy in adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).* Under the new coverage, Hizentra will be covered under the same benefit…

Read More about Medicare B will cover an immunoglobulin therapy for patients with CIDP, starting July 18, 2021

Live Webinar! CIDP: Improving Timely Diagnosis, Assessment, and Treatment (For Physicians Only)

Live Date: August 5, 2021 Time: 11:30am ET Program Expiration: August 5, 2022 While chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is the most common of the acquired immune-mediated demyelinating neuropathies, it remains a challenge to differentiate it from other immune-mediated inflammatory conditions. Clinicians may also find it difficult to recognize atypical presentations of CIDP. These issues…

Read More about Live Webinar! CIDP: Improving Timely Diagnosis, Assessment, and Treatment (For Physicians Only)

Live Webinar! Becoming Empowered with CIDP: Making My Voice Heard

We are pleased to announce a new, live video education session: “Becoming Empowered with CIDP: Making My Voice Heard” live on Thursday, August 5, 2021 at 10:00 AM ET.  An expert panel of neurology and pharmacy clinicians, as well as a patient with CIDP, will discuss the disease and review the questions every patient should…

Read More about Live Webinar! Becoming Empowered with CIDP: Making My Voice Heard

Angela’s Adaptive Devices

Written by Angela Patton Angela Patton is a member of GBS|CIDP’s Advisory Committee. In 2017, after an eight months struggle for a proper diagnosis, Angela was diagnosed with CIDP.  Here is Angela’s story… I was barely able to walk, and struggled during this time in my educational, and professional life. I have been on various…

Read More about Angela’s Adaptive Devices

FDA Warning for Guillain–Barre Syndrome and the Johnson & Johnson COVID-19 Vaccine

A Statement from the Foundation Global Medical Advisory Board The Washington Post and New York Times published on July 12, 2021 articles of a report by the FDA regarding cases of purported GBS after receiving the Johnson and Johnson COVID 19 vaccine.  Approximately 100 reports of suspected GBS were experienced by 12.8 million subjects who…

Read More about FDA Warning for Guillain–Barre Syndrome and the Johnson & Johnson COVID-19 Vaccine